Small molecule · Antagonist of histamine H1 receptor (HRH1) · developed by Chattem Sanofi
Levocetirizine is the active enantiomer of cetirizine, a selective histamine H1 receptor antagonist that competes with endogenous histamine at peripheral H1 receptors. It is studied in allergic rhinitis and is used for allergic symptoms and urticaria.
Summary written with AI from the sources listed at the end of this page.
From the indications section of the FDA label (version of Jul 22, 2025). Read the full label for the exact wording, limitations and safety information.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT00789152 | Phase 3 | Allergic Rhinitis | Completed | OGN |
| NCT05565729 | Phase 1 | Healthy | Completed | NKTR |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Allergic RhinitisHealthy
Updated Nov 15, 2026.